The Department of Ophthalmology maintains a strong commitment to medical research, which contributes to advances in ophthalmology and related areas of medicine through involvement in clinical investigations. Such research seeks to conquer eye disease, prevent blindness, and restore vision.

Why Should I Participate in a Clinical Trial?

Participation in clinical trials helps researchers uncover better ways to prevent, diagnose, treat, and understand diseases of the eye. In addition, clinical trials provide access to treatments which are otherwise unavailable.The information gained from clinical trials helps other people facing similar conditions.

Cornea, External Disease and Refractive Surgery

• Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
  ClinicalTrials.gov Identifier: NCT03992417. MSSM IRB Study ID is STUDY-21-00163.
  Study PI is Sumayya Ahmad, MD. Contact Information is: Harriet Lloyd, 212-979-4672, 646-943-7925, hlloyd@nyee.edu
• A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study)
  ClinicalTrials.gov Identifier: NCT04957758, MSSM IRB Study ID is STUDY-21-00741.
  Study PI is Sumayya Ahmad, MD. Contact Information is: Harriet Lloyd, 212-979-4672, 646-943-7925, hlloyd@nyee.edu
• Zoster Eye Disease Study

Glaucoma

• Nailfold Video Capillaroscopy as a Marker of Microvascular Changes in Patients with Primary Open Angle and Exfoliative Glaucoma
• Integration of clinical measures and theoretical modeling to quantify sectorial specific changes in ocular structure, function, and hemodynamics
  MSSM IRB ID: STUDY-20-00198
  Study PI is Alon Harris, PhD. Contact Information is: Alice Verticchio, MD, (317) 603-2446, alice.verticchio@mssm.edu

Retina

• IIT Age-related Macular Degeneration (AMD) and Cardiovascular Disease
• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
• A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)
• Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)
• Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
• Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
• Telemedicine in Age-Related Macular Degeneration (AMD)
• A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema,
  ClinicalTrials.gov Identifier: NCT04857996, MSSM IRB Study ID: STUDY-21-00898
  Study PI is Ronald Gentile, MD. Contact Information is: Katy Tai, 212-979-4251, 646943-7925, ktai@nyee.edu
• HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
  ClinicalTrials.gov Identifier: NCT04424290, MSSM IRB Study ID; STUDY-20-00643
  Study PI is Richard Rosen, MD. Contact Information is: Katy Tai, 212-979-4251, 646943-7925, ktai@nyee.edu

Office of Research Services

Research conducted by Icahn School of Medicine at Mount Sinai faculty, at the New York Eye and Ear Infirmary of Mount Sinai, is subject to Mount Sinai’s ethical and legal requirements for the conduct and oversight of human research. The Office of Research Services (ORS) serves as a central resource for the Mount Sinai Health System research community, and oversight of human subjects research is provided by the Program for the Protection of Human Subjects (PPHS).